School of Medicine
Showing 11-19 of 19 Results
-
Pema Richeson
Research Program Manager, Pathology - Montine Lab
Current Role at StanfordProgram Manager | Team eDyNAmiC, Cancer Grand Challenges
Project Manager | PPMI Pathology Core
Center Administrator | Stanford SeroNet Center of Excellence -
Kerri E. Rieger, MD, PhD
Clinical Professor, Pathology
Clinical Professor, DermatologyBioDr. Rieger is a Clinical Professor of Pathology and Dermatology at Stanford University. She received her M.D., Ph.D. from Stanford University School of Medicine and completed her Dermatology Residency and Dermatopathology Fellowship at Stanford University. She is board certified in Dermatology and Dermatopathology. She evaluates skin specimens in the Pathology department, where her interests include histopathologic findings in cutaneous lymphoma, hospitalized patients, and patients with autoimmune disease. She also sees patients in the Stanford dermatology clinic in Portola Valley, where her clinical interest is adult general dermatology.
-
Suman Rimal
Postdoctoral Scholar, Pathology
BioResearch interests: Genetic mechanism underlying mitochondrial pathology, neurodegeneration, and muscle loss using Drosophila as a model organism.
-
Theodore Roth
Assistant Professor of Pathology
Current Research and Scholarly InterestsThe Roth Lab develops, applies, and translates scalable genetic manipulation technologies in primary human cells and complex in vivo tissue environments. Working with students, trainees, and staff with backgrounds across bioengineering, genetics, immunology, oncology, and pathology, the lab has developed CRISPR-All, a unified genetic perturbation language able to arbitrarily and combinatorially examine genetic perturbations across perturbation type and scale in primary human cells. Ongoing applications of CRISPR-All in the lab have revealed surprising capacities to synthetically engineer human cells beyond evolved cellular states. These new capacities to perturb human cell’s genetics beyond their evolved functionality drives ongoing work to understand the biology and therapeutic potential of synthetic cell state engineering - in essence learning how to build new human genes tailor made for a specific cell and specific environment to drive previously inaccessible therapeutic cellular functions.
